中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2014年
2期
83-87
,共5页
樊祥山%孙琦%陈洁宇%章宜芬%吴鸿雁%周强%郑玉声%孟凡青
樊祥山%孫琦%陳潔宇%章宜芬%吳鴻雁%週彊%鄭玉聲%孟凡青
번상산%손기%진길우%장의분%오홍안%주강%정옥성%맹범청
胃肿瘤%基因,erbB-2%免疫组织化学%质量控制
胃腫瘤%基因,erbB-2%免疫組織化學%質量控製
위종류%기인,erbB-2%면역조직화학%질량공제
Stomach neoplasms%Genes,erbB-2%Immunohistochemistry%Quality control
目的 探讨胃癌HER2蛋白表达的免疫组织化学检测结果的影响因素.方法 比较南京大学医学院附属鼓楼医院2007至2009年间(G1组)和2012至2013年间(G2组)两个时间段内1 471例胃癌根治标本中HER2的免疫组织化学(IHC)检测结果,并分析可能影响胃癌中HER2阳性表达的相关因素.结果 G1组胃癌根治标本957例,采用手工方法进行IHC检测,HER2一抗购自Dako公司(克隆号为A0485),标本采用4%甲醛液固定,所有病例由不同医师评判;结果显示HER23+者占9.5% (91/957),HER2 3+或HER2 2+者占21.7%(208/957).G2组胃癌根治标本514例,采用Roche公司自动化染色系统进行IHC检测,一抗购自Roche公司(克隆号为4B5),检测标本均经4%中性缓冲甲醛液固定,所有病例均由专门小组共同评判;结果显示HER2 3+者占14.4%(74/514),HER2 3+或HER2 2+者占27.2% (140/514).G2组胃癌HER2 3+者和HER2 3 +/2+者均显著高于G1组(P<0.05).结论 胃癌HER2规范化IHC检测可能与标本固定液类型、HER2抗体选择、IHC检测方法以及染色结果评估经验等有关,对上述方面条件的优化能够明显提高HER2阳性胃癌的检出率.
目的 探討胃癌HER2蛋白錶達的免疫組織化學檢測結果的影響因素.方法 比較南京大學醫學院附屬鼓樓醫院2007至2009年間(G1組)和2012至2013年間(G2組)兩箇時間段內1 471例胃癌根治標本中HER2的免疫組織化學(IHC)檢測結果,併分析可能影響胃癌中HER2暘性錶達的相關因素.結果 G1組胃癌根治標本957例,採用手工方法進行IHC檢測,HER2一抗購自Dako公司(剋隆號為A0485),標本採用4%甲醛液固定,所有病例由不同醫師評判;結果顯示HER23+者佔9.5% (91/957),HER2 3+或HER2 2+者佔21.7%(208/957).G2組胃癌根治標本514例,採用Roche公司自動化染色繫統進行IHC檢測,一抗購自Roche公司(剋隆號為4B5),檢測標本均經4%中性緩遲甲醛液固定,所有病例均由專門小組共同評判;結果顯示HER2 3+者佔14.4%(74/514),HER2 3+或HER2 2+者佔27.2% (140/514).G2組胃癌HER2 3+者和HER2 3 +/2+者均顯著高于G1組(P<0.05).結論 胃癌HER2規範化IHC檢測可能與標本固定液類型、HER2抗體選擇、IHC檢測方法以及染色結果評估經驗等有關,對上述方麵條件的優化能夠明顯提高HER2暘性胃癌的檢齣率.
목적 탐토위암HER2단백표체적면역조직화학검측결과적영향인소.방법 비교남경대학의학원부속고루의원2007지2009년간(G1조)화2012지2013년간(G2조)량개시간단내1 471례위암근치표본중HER2적면역조직화학(IHC)검측결과,병분석가능영향위암중HER2양성표체적상관인소.결과 G1조위암근치표본957례,채용수공방법진행IHC검측,HER2일항구자Dako공사(극륭호위A0485),표본채용4%갑철액고정,소유병례유불동의사평판;결과현시HER23+자점9.5% (91/957),HER2 3+혹HER2 2+자점21.7%(208/957).G2조위암근치표본514례,채용Roche공사자동화염색계통진행IHC검측,일항구자Roche공사(극륭호위4B5),검측표본균경4%중성완충갑철액고정,소유병례균유전문소조공동평판;결과현시HER2 3+자점14.4%(74/514),HER2 3+혹HER2 2+자점27.2% (140/514).G2조위암HER2 3+자화HER2 3 +/2+자균현저고우G1조(P<0.05).결론 위암HER2규범화IHC검측가능여표본고정액류형、HER2항체선택、IHC검측방법이급염색결과평고경험등유관,대상술방면조건적우화능구명현제고HER2양성위암적검출솔.
Objective To study the potential factors in influencing the performance of immunohistochemical testing for HER2 protein in gastric cancers.Methods The HER2 protein expression status of 1 471 surgically resected archival gastric cancer cases in Drum Tower Hospital collected during two different periods was retrospectively analyzed.The materials included 957 cases tested during the period from 2007 to 2009 (group 1) and 514 cases from 2012 to 2013 (group 2).The test procedures and results observed during these two periods were compared.Results The percentages of score 3 HER2 protein expression (14.4%,74/514 versus 9.5%,91/957) and score 2 or score 3 HER2 protein expression (27.2%,140/514 versus 21.7%,208/957) were both higher in group 2 than in group 1 (P < 0.05).In group 1,the cancer tissue was fixed in 10% formalin,stained manually with HER2 antibody A0485 (Dako)and assessed by different pathologists.In group 2,the tissue was fixed in 10% neutral buffered formalin (pH 7.2),stained using automated immunostaining system (Roche Benchmark XT) with HER2 antibody 4B5 (Ventana) and assessed by a specialized team of pathologists.Conclusion The results of HER2 immunostaining in gastric cancer are influenced by a number of factors including type of fixative,clone number of primary antibody,staining methods and experience of pathologists.